The concept of liquid biopsy is based on the knowledge that blood or secretions from the body contain tumor cells, nucleic acids, cellular components, and tumor metabolites (1).
An innovative test, named TriOx, analyses multiple features of DNA in the peripheral blood across six types of cancer (colorectal, oesophageal, pancreatic, renal, ovarian, and breast) and can distinguish between individuals with and without cancer (1):
A statement from NIHR describes this intervention:
"..researchers combined a cutting-edge DNA analysis technique, called TAPS, with machine learning, to analyse multiple key features from the DNA circulating in the blood.
The TriOx test was evaluated on blood samples from patients with and without cancer. It demonstrated the ability to detect cancers (including early-stage cancers) and distinguish between people who had cancer and those that did not with 94.9% sensitivity and 88.8% specificity. For any cancer test, it's important to minimise the number of people without cancer who are subjected to unnecessary procedures, while helping those with cancer to receive treatment sooner.
The cancer types evaluated in this study were:
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.